Our results suggest that resistin may exacerbate NAFLD in metabolic syndrome through upregulating inflammatory cytokines and hepatic PEPCK and SREBP-1c. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.